Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study
International Journal of Urology · 2026-05 · 33 (5)
DOI: 10.1111/iju.70505 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, online erschienen am 20.05.2026. Verfasst von Koji Iinuma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medicine, Gifu University, Gifu, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Pembrolizumab is indicated as adjuvant therapy after nephrectomy in patients with high‐risk renal cell carcinoma (RCC). However, data regarding the occurrence of treatment‐related adverse events (TRAEs) associated with pembrolizumab in real‐world clinical settings in Japanese patients remain limited. In this study, we aimed to assess the clinical safety of adjuvant pembrolizumab therapy in Japan.
Methods
This multicenter, retrospective, observational study enrolled patients who received adjuvant pembrolizumab therapy for RCC at five facilities in Japan between August 2022 and March 2025. The primary endpoint was the occurrence of TRAEs, which were classified by grade according to the Common Terminology Criteria for Adverse Events version 5.0. Secondary endpoints focused on disease‐free survival (DFS) and overall survival (OS).
Results
This study enrolled 35 patients and had a median follow‐up period of 7.0 months (interquartile range: 2.0–14.0). TRAEs occurred in 13 patients (37.1%), including two (5.7%) with grade ≥ 3 events. Five patients (14.3%) discontinued pembrolizumab treatment because of TRAEs, and no treatment‐related deaths were observed. Grade ≥ 3 TRAEs included one case each of erythema multiforme, myocarditis, gastrointestinal perforation, and myasthenia gravis. During follow‐up, no disease recurrence or death was observed, and the median DFS and OS were not achieved.
Conclusions
The safety profile of pembrolizumab as an adjuvant therapy was found to be acceptable in Japanese patients with high‐risk RCC. Therefore, postoperative adjuvant pembrolizumab following surgical intervention may be recommended as a treatment option for eligible patients in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medicine, Gifu University, Gifu, Japan.
- Department of Urology, Graduate School of Medicine, Mie University, Tsu, Japan.
- Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Urology, Gifu Prefectural General Medical Center, Gifu, Japan.
- Department of Urology, Ogaki Municipal Hospital, Ogaki, Japan.
ORCID-Profile: Koji Iinuma, Keita Nakane
Förderung
- Japan Society for the Promotion of Science (JSPS) KAKENHI
Zitieren
APA
Iinuma, K., Nishikawa, K., Sano, Y., Ozawa, K., Yamada, T., Taniguchi, T., Nakane, K., Inoue, T., Akamatsu, S., & Koie, T. (2026). Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology, 33(5). https://doi.org/10.1111/iju.70505
Vancouver
Iinuma K, Nishikawa K, Sano Y, Ozawa K, Yamada T, Taniguchi T, et al. Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology. 2026;33(5). doi:10.1111/iju.70505
BibTeX
@article{Iinuma2026,
author = {Iinuma, Koji and Nishikawa, Kohei and Sano, Yuta and Ozawa, Kaori and Yamada, Toyohiro and Taniguchi, Tomoki and Nakane, Keita and Inoue, Takahiro and Akamatsu, Shusuke and Koie, Takuya},
title = {Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {5},
doi = {10.1111/iju.70505}
}
EUVIMED